ID Vaccine Secures GMP Manufacturing Source for Group A Streptococcus Vaccine.

VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--June 20, 1997-- ID Biomedical Corpor(TSE IDB., NASDAQ IDBEF.) ID Biomedical Corporation announced today that its subsidiary, ID Vaccine, has entered into a contract manufacturing agreement with The Collaborative BioAlliance of Stony Brook, NY, for the Good Manufacturing Practices (GMP) production of its group A streptococcus (GAS) vaccine.

Manufacturing product under GMP conditions is an essential step prior to human testing of new vaccine candidates. ID Vaccine intends to file an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) for approval to begin Phase I human clinical trials of its GAS vaccine in the first quarter of 1998.

ID Vaccine President, Todd R. Patrick, says the Company is pleased to be starting this important phase of product development.

"Collaborative BioAlliance has the appropriate facilities and expertise to assist us in manufacturing our GAS vaccine as required by international regulatory bodies," he says. "Once this task is completed, we will engage a Contract Research Organization to carry out the pre IND toxicity studies required by the FDA."

GAS causes a wide variety of diseases including "strep throat" (acute pharyngitis). According to the Centers for Disease Control in the US, 25-40 million people in North America get "strep throat" every year at an estimated cost of $2 billion to the US healthcare system. GAS is also responsible for impetigo (a skin infection), invasive fasciitis (also known as flesh-eating disease), toxic shock syndrome and rheumatic fever.

The Collaborative BioAlliance (CBA), located in Stony Brook, NY, a wholly owned subsidiary of The Collaborative Group, is dedicated to the contract production of biologics for use in therapeutic and diagnostic applications. The CBA has considerable expertise in the area of controlled delivery systems such as liposomes, colloidal suspensions and polymer technologies.

ID Biomedical Corporation is a North American biotechnology company that is emerging as a leader in two fields of medicine: gene detection and subunit vaccines. The Company's gene detection platform, Cycling Probe Technology (CPT), has been shown to have significant cost, time and ease of use advantages over comparable systems currently on the market. ID Biomedical's first two products in development are tests for MRSA (in independent clinical studies) and VRE, which use CPT to detect the genes responsible for antibiotic resistance. The Company, through it's subsidiary ID Vaccine, is also engaged in the development of subunit vaccines against infectious diseases. The Company's lead products are a vaccine against group A streptococcus and a vaccine for the prevention of tuberculosis which has been licensed to Pasteur Merieux Connaught, a member of the Rhone-Poulenc Group.

The foregoing information includes forward-looking statements concerning, among other things, management's plans and objectives for future corporate objectives. All such forward-looking statements are, by necessity, only estimates of future results and actual results achieved by the Company may differ materially from these statements due to a number of factors, including including i) the Company's ability to successfully complete preclinical development and manufacturing and obtain timely regulatory approval, and ii) decisions, and the timing of decisions, made by the health regulatory agencies regarding approval of the Company's products for human testing. The Company assumes no obligation to update these forward- looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such statements.

CONTACT: ID Biomedical Corporation

Hugh Notman, 604/ 431-9314

http://www.idbiomed.com

e-mail: [e-mail]

or

James Hoggan & Associates

Mark Reis, 604/ 739-7500